Prediction of trifluridine/tipiracil (TAS-102) effectiveness in patients with refractory metastatic colorectal cancer (mCRC): Real-life data from the Czech Republic.

被引：0
|
作者：
Grell, Peter
Dvorak, Josef
Vocka, Michal
John, Stanislav
Tuskova, Helena
Buchler, Tomas
Borilova, Simona
Selingerova, Iveta
Vyzula, Rostislav
Petruzelka, Lubos B.
Kiss, Igor
Obermannova, Radka
机构：
[1] Masaryk Mem Canc Inst, Brno, Czech Republic
[2] Charles Univ Med Sch & Teaching Hosp, Hradec Kralove, Czech Republic
[3] Charles Univ Prague, Prague, Czech Republic
[4] Dept Oncol & Radiotherapy, Hradec Kralove, Czech Republic
[5] Charles Univ Prague, Fac Med 1, Dept Oncol, Prague, Czech Republic
[6] Thomayer Univ Hosp, Prague, Czech Republic
[7] Masaryk Mem Canc Inst, Reg Ctr Appl Mol Oncol, Brno, Czech Republic
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e15102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15102
引用
收藏
页数：1
相关论文
共 50 条
  • [21] TAS-102 (trifluridine/tipiracil) plus bevacizumab versus TAS-102 alone as salvage treatment options for metastatic colorectal cancer in routine clinical practice
    Shin, J. E.
    Cho, S.
    Lee, J.
    Kim, S. T.
    ANNALS OF ONCOLOGY, 2024, 35 : S1443 - S1443
  • [22] Pharmacokinetic and pharmacodynamic (PK/PD) analysis results from the phase 3 RECOURSE trial of trifluridine and tipiracil (TAS-102) versus placebo (pbo) in patients (pts) with refractory metastatic colorectal cancer (mCRC)
    Yoshino, T.
    Cleary, J.
    Mayer, R.
    Yoshida, K.
    Makris, L.
    Yamashita, F.
    Ohtsu, A.
    Lenz, H-J.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [23] Safety for trifluridine/tipiracil (TAS-102) with bevacizumab combination in patients with refractory metastatic colorectal cancer in real-world clinical practice: The single-institutional experience.
    Yasuda, Kayo
    Kotani, Daisuke
    Kuboki, Yasutoshi
    Fukuoka, Shota
    Bando, Hideaki
    Kawazoe, Akihito
    Nakamura, Yoshiaki
    Shitara, Kohei
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [24] Phase II trial of trifluridine/tipiracil (TAS-102) in patients with advanced refractory biliary tract cancer (BTC)
    Chakrabarti, S.
    Zemla, T.
    Ou, F-S.
    Fruth, B.
    Ahn, D.
    Borad, M. J.
    Hartgers, M. L.
    Wessling, J.
    Walkes, R. L.
    Alberts, S.
    McWilliams, R. R.
    Liu, M. C.
    Mahipal, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] Real-world data of TAS-102 therapy in refractory metastatic colorectal cancer (mCRC): The experience of the University Hospital of Montreal (CHUM).
    El Khoury, Reem
    Tehfe, Jad
    Ouellet, Marie
    Aubin, Francine
    Lougnarath, Rasmy
    Ayoub, Jean-Pierre M.
    Tehfe, Mustapha
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 137 - 137
  • [26] Prognostic factors in patients receiving trifluridine/tipiracil for refractory metastatic colorectal cancer in the real-life setting: The ROS study
    Garcia-Alfonso, P.
    Reina Zoilo, J.
    Mata Velasco, E.
    Llanos, M.
    Illan Varella, A.
    Safont Aguilera, M.
    Delgado Urena, M.
    Castanon, C.
    Pimentel, P.
    Alonso Orduna, V.
    Mendez, J.
    Rivera Herrero, F.
    Siso, I.
    Rodriguez-Pascual, J.
    Gravalos Castro, C.
    Afonso, R.
    Fernandez Ranada, I.
    Grandez, R.
    Moreno, M.
    Munoz, A. Lopez
    Garcia-Paredes, B.
    Aranda, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S113 - S113
  • [27] Safety and Efficacy of Trifluridine-Tipiracil Hydrochloride Oral Combination (TAS-102) in Patients with Unresectable Colorectal Cancer
    Narihiro, Satoshi
    Suwa, Katsuhito
    Ushigome, Takuro
    Ohtsu, Masamichi
    Ryu, Syunjin
    Shimoyama, Yuya
    Okamoto, Tomoyoshi
    Yanaga, Katsuhiko
    IN VIVO, 2018, 32 (06): : 1643 - 1646
  • [28] Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
    Kiyoaki Sugiura
    Yuki Seo
    Takayuki Takahashi
    Hideyuki Tokura
    Yasuhiro Ito
    Motomu Tanaka
    Norihiro Kishida
    Yusuke Nishi
    Yoshihiko Onishi
    Hikaru Aoki
    BMC Gastroenterology, 21
  • [29] Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
    Sugiura, Kiyoaki
    Seo, Yuki
    Takahashi, Takayuki
    Tokura, Hideyuki
    Ito, Yasuhiro
    Tanaka, Motomu
    Kishida, Norihiro
    Nishi, Yusuke
    Onishi, Yoshihiko
    Aoki, Hikaru
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [30] COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AND TAS-102 IN REFRACTORY METASTATIC COLORECTAL CANCER
    Cho, S. K.
    Hay, J. W.
    Barzi, A.
    VALUE IN HEALTH, 2018, 21 : S1 - S1
12345